Evaluation and Follow-up of People With Tick-borne Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04318925|
Recruitment Status : Recruiting
First Posted : March 24, 2020
Last Update Posted : August 2, 2021
Lyme disease is the most common tick-borne disease in the United States, but other diseases transmitted by ticks have also been on the rise in recent years. Early symptoms of a tickborne disease include fever, headache, fatigue and possible rash. Researchers want to collect information and samples from people with Lyme disease and other tick-borne illnesses to better understand and diagnose these diseases.
To evaluate and follow people with tick-borne diseases to help researchers learn more about these infections.
People ages 18 and older who have or are suspected of having a tick-borne infection.
Participants will have an initial visit, and visits about 1, 6, and 12 months later. The visits can include a physical exam, blood tests, collection of blood, urine and saliva samples for research, and filling out health-related questionnaires. Participants who have the rash of Lyme disease may be invited to have up to 3 skin punch biopsies of the rash for research.
|Condition or disease|
|Lyme Disease Tick-Borne Disease|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Evaluation and Follow-up of Patients With Tick-borne Diseases|
|Estimated Study Start Date :||August 5, 2021|
|Estimated Primary Completion Date :||December 31, 2029|
|Estimated Study Completion Date :||May 31, 2030|
Persons with diagnosed or suspected tick-borne disease age >=18 years
- Define percentage of participants with suspected, probable, or confirmed TBD, as defined by the CDC case definitions and TBD testing, and measure clinical outcome using established assessment tools and questionnaires. [ Time Frame: Assessed annually. ]Identify type of tick-borne disease and clinical outcome.
- Utilize current and future technologies to develop new direct and indirect tests and biomarkers for TBDs. These can include, but not limited to, antibody-based testing, antigen-based testing, molecular-based testing, culture. [ Time Frame: Ongoing ]Will use samples for developing novel diagnostic testing.
- Evaluation of the immune response to the pathogens. These can include, but are not limited to, cytokine testing, cellular response testing, antibody profile, metabolomics, proteomics, transcriptomics, and others. [ Time Frame: Ongoing ]Will use samples to explore human immune response to TBDs.
- Genomic-based testing for research on pathogen virulence and mutations. [ Time Frame: Ongoing ]Will use samples to explore pathogen.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04318925
|Contact: Siu-Ping Turk, R.N.||(301) email@example.com|
|United States, Maryland|
|University of Maryland Baltimore, Department of Medicine||Recruiting|
|Baltimore, Maryland, United States, 21201|
|Contact: Kalpana Shere- Wolfe, MD 410-328-9102 firstname.lastname@example.org|
|Principal Investigator:||Adriana R Marques, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|